Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Overview of patient characteristics

From: Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

Trial
(reference)
Treatment arm RF status
(% positive)
Gender (% F) Mean age (years) Mean years since diagnosis Mean n of prior DMARDs % pts on NSAIDs % pts on corticoid steriods Mean TJC Mean SJC Mean pts pain1 (100-mm VAS) Mean pts GA 2 (100-mm VAS) Mean phs GA3 (100-mm VAS) Mean HAQ-DI Mean CRP (mg/l) Mean ESR (mm/h)
Abatacept studies
AIM [14, 18] PBO + MTX;
ABA 10 mg/kg every four weeks + MTX
81.8 77.8 51.5 8.5 1.3 85.5 72.1 31.0 21.4 63.3 62.7 68.0 1.70 33 nr
   78.5 81.7 50.4 8.9 1.2 82.6 68.5 32.3 22.1 65.9 62.8 67.4 1.70 28  
Kremer et al. 2005, Kremer et al. 2003 [16, 17] PBO + MTX 90.0 66.0 54.7 8.9 21% nr 67.2 29.2 21.8 65.2 62.8 63.3 1.00 32 nr
  ABA 2 mg/kg every four weeks + MTX 90.0 63.0 54.4 9.7 18.1%   67.6 28.2 20.2 64.5 59.4 61.0 1.00 32  
  ABA 10 mg/kg every four weeks + MTX 99.0 75.0 55.8 9.7 16.5%   60.0 30.8 21.3 62.1 60.1 62.1 1.00 29  
ATTEST [15] ABA 10 mg/kg every four weeks + MTX 87.2 83.3 49.0 7.9 1.7 85.3 75.6 31.6 21.3 nr nr nr 1.80 31 49.4
  PBO + MTX 77.3 87.3 49.4 8.4 1.8 84.5 70.0 30.3 20.1     1.80 27 47.0
  INF 3 mg/kg every eight weeks +MTX 84.8 82.4 49.1 7.3 1.7 86.1 71.5 31.7 20.3     1.70 33 47.8
Adalimumab studies
ARMADA [25] PBO + MTX mean IU/liter +- SD reported 82.3 56.0 11.1 3.0 nr nr 28.7 16.9 57.2 58.0 58.9 1.64 31 nr
  ADA 20 mg every other week + MTX   75.4 53.5 13.1 3.0    28.5 17.6 55.1 57.6 60.5 1.52 28  
  Adalimumab 40 mg every other week + MTX   74.6 57.2 12.2 2.9    28.0 17.3 53.0 56.9 58.7 1.55 21  
  ADA 80 mg every other week + MTX   75.3 55.5 12.8 3.1    30.3 17.0 55.0 58.8 62.6 1.55 28  
DE019 [24] ADA 40 mg every other week + MTX 81.6 76.3 56.1 11.0 2.4 nr nr 27.3 19.3 55.9 52.7 62.0 1.45 18 nr
  ADA 20 mg weekly + MTX 81.2 75.5 57.3 11.0 2.4    27.9 19.6 55.2 51.9 61.6 1.44 14  
  PBO + MTX 89.5 73.0 56.1 10.9 2.4    28.1 19.0 56.3 54.3 61.3 1.48 18  
Certolizumab Pegol studies
RAPID I [26, 27, 29] PBO + MTX 82.8 83.9 52.2 6.2 1.4 nr nr 29.8 21.2 nr nr nr 1.70 16 45.0
  CZP 200 mg every other week + MTX 79.6 82.4 51.4 6.1 1.3    30.8 21.7     1.70 16 43.5
  CZP 400 mg every other week + MTX 83.6 83.6 52.4 6.2 1.3    31.1 21.5     1.70 14 42.5
RAPID II [28, 29] PBO + MTX 78.2 84.3 51.5 5.6 1.2 nr nr 30.4 21.9 59.9 59.9 65.7 1.60 14 40.8
  CZP 200 mg every other week + MTX 77.5 83.7 52.2 6.1 1.2    30.1 20.5 61.8 62.4 64.3 1.60 14 43.7
  CZP 400 mg every other week + MTX 75.5 78.0 51.9 6.5 1.3    30.0 21.0 60.5 61.1 62.8 1.60 13 39.1
Etanercept studies
Weinblatt et al. 1999 [32] PBO + MTX 90.0 73.0 53.0 13.0 2.8 80.0 70.0 28.0 17.0 56.0 60.0 65.0 1.50 26 36.0
  ETN 25 mg twice weekly + MTX 84.0 90.0 48.0 13.0 2.7 75.0 53.0 28.0 20.0 50.0 60.0 60.0 1.50 22 25.0
TEMPO [30, 31] PBO + MTX 71.0 79.0 53.0 6.8 2.3 86.0 64.0 33.1 22.6 nr nr nr nr 26 nr
  ETN 25 mg twice weekly 75.0 77.0 53.2 6.3 2.3 88.0 57.0 35.0 23.0      32  
  ETN 25 mg twice weekly + MTX 76.0 74.0 52.5 6.8 2.3 88.0 62.0 34.2 22.1      30  
Golimumab studies
GO-FORWARD [33, 34] PBO + MTX 81.2 82.0 52.0 6.5 70.74 nr nr 21.0 12.0 57.0 53.0 56.5 1.25 8 nr
  GOL 100 mg every 4 weeks 83.5 78.9 51.0 5.9 75.9    22.0 11.0 60.0 56.0 58.0 1.38 9  
  GOL 50 mg every 4 weeks + MTX 86.5 80.9 52.0 4.5 78.7    26.0 13.0 61.0 60.0 61.0 1.38 10  
  GOL 100 mg every four weeks + MTX 84.3 80.9 50.0 6.7 75.3    23.0 12.0 64.0 59.0 61.0 1.38 9  
Infliximab studies
ATTRACT [35, 36] PBO + MTX 77.0 80.0 51.0 8.9 2.5 72.0 64.0 24.0 19.0 67.0 62.0 65.0 1.80 30 nr
  INF 3 mg/kg every eight weeks +MTX 84.0 81.0 56.0 8.4 2.8 79.0 63.0 32.0 19.0 70.0 66.0 61.0 1.80 31  
  INF 3 mg/kg every four weeks +MTX 80.0 77.0 51.0 7.2 2.6 76.0 53.0 31.0 20.0 69.0 57.0 62.0 1.80 20  
  INF 10 mg/kg every eight weeks +MTX 82.0 77.0 55.0 9.0 2.5 77.0 57.0 30.0 20.0 67.0 64.0 64.0 1.80 25  
  INF 10 mg/kg every four weeks +MTX 82.0 73.0 52.0 8.7 2.5 68.0 65.0 35.0 23.0 66.0 60.0 60.0 1.50 24  
Rituximab studies
DANCER [39, 40] PBO + MTX 100
(efficacy analyses)
80.0 51.1 9.3 2.2 nr nr 35.0 21.0 nr nr nr 1.70 33 40.0
  RTX 500 mg * two injections + MTX 100 83.0 51.4 11.1 2.5    33.0 22.0     1.80 32 45.0
  RTX 1,000 mg * two injections + MTX 100 80.0 51.1 10.8 2.5    32.0 22.0     1.70 30 41.0
Edwards et al. 2004 [41] PBO + MTX 100 80.0 54.0 11.0 2.6 nr nr 32.0 19.0 nr nr nr nr 32 52.0
  RTX 1,000 mg * two injections 100 73.0 54.0 9.0 2.5    34.0 21.0      26 47.0
  RTX 1,000 mg * two injections +cyclophosphamide 100 83.0 53.0 10.0 2.6    33.0 19.0      40 55.0
  RTX 1,000 mg * two injections + MTX 100 75.0 54.0 12.0 2.5    32.0 23.0      29 53.0
Tocilizumab studies
OPTION [43, 44] PBO + MTX 78.0 78.0 50.6 7.8 1.7 68.0 nr 32.8 20.7 57.3 63.6 63.7 1.50 24 49.7
  TCZ 4 mg/kg every four weeks + MTX 83.0 82.0 51.4 7.4 1.5 68.0   33.2 20.0 60.7 65.6 63.6 1.60 28 49.2
  TCZ 8 mg/kg every four weeks + MTX 71.0 85.0 50.8 7.5 1.5 66.0   31.9 19.5 59.9 64.8 64.0 1.60 26 51.2
LITHE [42] PBO + MTX nr nr nr nr nr nr nr nr nr nr nr nr 1.5 nr nr
  TCZ 4 mg/kg every four weeks + MTX              1.5   
  TCZ 8 mg/kg every four weeks + MTX              1.5   
  1. The treatment arms in grey were not used in the network meta-analysis but are included as part of the trials.
  2. 1Patients assessment of pain (Pts Pain); 2Patients global assessment of disease activity (Pts GA); 3Physician global assessment of disease activity (Phs GA); 4% Patients with previous use of DMARD other than MTX. ABA, abatacept; ADA, adalimumab; CRP, C-reactive protein; CZP, certolizumab pegol; DMARD, Disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; GA, global assessment; GOL, golimumab; HAQ, health assessment questionnaire; INF, infliximab; MTX, methotrexate; nr, not recorded; NSAID, non-steroidal anti-inflammatory drug; PBO, placebo; Pts, patients; RF, rheumatoid factor; RTX, rituximab; SJC, swollen joint count; TCZ, tocilizumab; TJC, tender joint count;
  3. No data for patient characteristics were available for the SERENE study.